{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T03:58:04Z","timestamp":1794887884073,"version":"4.9.1"},"reference-count":93,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012264","name":"NIH","doi-asserted-by":"publisher","award":["HL181016"],"award-info":[{"award-number":["HL181016"]}],"id":[{"id":"10.13039\/501100012264","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012264","name":"NIH","doi-asserted-by":"publisher","award":["HL105699"],"award-info":[{"award-number":["HL105699"]}],"id":[{"id":"10.13039\/501100012264","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012264","name":"NIH","doi-asserted-by":"publisher","award":["HL174996"],"award-info":[{"award-number":["HL174996"]}],"id":[{"id":"10.13039\/501100012264","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012264","name":"NIH","doi-asserted-by":"publisher","award":["HL159428"],"award-info":[{"award-number":["HL159428"]}],"id":[{"id":"10.13039\/501100012264","id-type":"DOI","asserted-by":"publisher"}]},{"name":"American Heart Association Predoctoral Fellowship","award":["PRE1026591"],"award-info":[{"award-number":["PRE1026591"]}],"id":[{"id":"https:\/\/ror.org\/013kjyp64","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL171711"],"award-info":[{"award-number":["R01HL171711"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL181226"],"award-info":[{"award-number":["HL181226"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01HL165211"],"award-info":[{"award-number":["1R01HL165211"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01HL181091"],"award-info":[{"award-number":["1R01HL181091"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"American Heart Association Collaborative Sciences Award","award":["24CSA1255857"],"award-info":[{"award-number":["24CSA1255857"]}],"id":[{"id":"https:\/\/ror.org\/013kjyp64","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Heart failure with preserved ejection fraction (HFpEF) remains a significant therapeutic challenge. While GLP-1 receptor agonists (GLP-1RAs) show clinical promise, it remains unknown if their benefits are driven solely by weight loss or involve weight loss-independent mechanisms. We investigated the weight loss-independent effects of semaglutide in two preclinical models of cardiometabolic HFpEF: the ZSF1 Obese rat and the G\u00f6ttingen HFpEF minipig.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Male ZSF1 Obese rats (n = 12\/group) and female G\u00f6ttingen minipigs with \u2018two-hit\u2019 induced HFpEF (early intervention: n = 5\/group; delayed intervention: n = 4\/group) were treated with semaglutide at doses empirically determined to be non-weight-loss inducing. Comprehensive assessments included invasive hemodynamic (LVEDP, PCWP), echocardiography, and histological quantification of fibrosis and lipid burden. Delayed intervention utilized Cardiac MRI to quantify subcutaneous and ectopic fat depots. In rats, advanced multi-omics (NULISA plasma proteomics, single-cell RNA sequencing and tissue proteomics) were utilized to explore molecular mechanisms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In ZSF1 Obese rats, semaglutide significantly improved diastolic function (reducing LVEDP by \u223c60%) and attenuated cardiac hypertrophy (by \u223c30%), interstitial fibrosis, and cardiac lipid deposition in the absence of a significant weight loss. These functional benefits were conserved in the minipig HFpEF model, where treatment attenuated cardiac hypertrophy, left ventricular E\/e\u2032, normalized pulmonary capillary wedge pressure (PCWP) and reversed advanced hepatic bridging fibrosis. Delayed intervention in established HFpEF minipigs reversed diastolic dysfunction and significantly reduced ectopic lipid depots (intramyocardial, epicardial, and hepatic fat) without affecting subcutaneous fat or total body weight. Mechanistically, multi-omics analyses in the rat heart revealed that these benefits were driven by suppression of pro-fibrotic and hypertrophic signals and up-regulation of branched-chain amino acid (BCAA) catabolism and fatty acid oxidation pathways in cardiomyocytes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Semaglutide attenuates cardiac and hepatic remodelling in preclinical models of obesity-associated cardiometabolic HFpEF in the absence of profound weight loss. The conservation of these effects across male rodents and female swine supports their translational relevance, while future studies are needed to define dose equivalence and confirm GLP-1 receptor engagement in cardiac and hepatic tissues. These findings support further mechanistic investigation of weight loss-independent GLP-1 receptor agonist signalling in this HFpEF phenotype.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehag732","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:23:11Z","timestamp":1788520991000},"source":"Crossref","is-referenced-by-count":2,"title":["Semaglutide, independent of weight loss, attenuates cardiac and hepatic remodelling in experimental heart failure with preserved ejection fraction"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2437-1773","authenticated-orcid":false,"given":"Mahmoud H","family":"Elbatreek","sequence":"first","affiliation":[{"name":"Department of Cardiac Surgery, Smidt Heart Institute, Cedars-Sinai Medical Center , 127 S. San Vincente Boulevard, Los Angeles, CA 90048 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Cardiac Surgery, Smidt Heart Institute, Cedars-Sinai Medical Center , 127 S. San Vincente Boulevard, Los Angeles, CA 90048 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoman","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Cardiac Surgery, Smidt Heart Institute, Cedars-Sinai Medical Center , 127 S. San Vincente Boulevard, Los Angeles, CA 90048 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7815-4881","authenticated-orcid":false,"given":"Natalie D","family":"Gehred","sequence":"additional","affiliation":[{"name":"Departments of Anesthesiology & Perioperative Medicine, Medicine and Physiology, Molecular Biology Institute, David Geffen School of Medicine at University of California , Los Angeles, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5597-2067","authenticated-orcid":false,"given":"Tatiana","family":"Gromova","sequence":"additional","affiliation":[{"name":"Departments of Anesthesiology & Perioperative Medicine, Medicine and Physiology, Molecular Biology Institute, David Geffen School of Medicine at University of California , Los Angeles, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingshu","family":"Chen","sequence":"additional","affiliation":[{"name":"Gordian Biotechnology , South San Francisco, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Huerta","sequence":"additional","affiliation":[{"name":"Department of Cardiac Surgery, Smidt Heart Institute, Cedars-Sinai Medical Center , 127 S. San Vincente Boulevard, Los Angeles, CA 90048 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Muraoka","sequence":"additional","affiliation":[{"name":"Gordian Biotechnology , South San Francisco, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin Borch","family":"Jensen","sequence":"additional","affiliation":[{"name":"Gordian Biotechnology , South San Francisco, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Kartha","sequence":"additional","affiliation":[{"name":"Gordian Biotechnology , South San Francisco, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Carrico","sequence":"additional","affiliation":[{"name":"Gordian Biotechnology , South San Francisco, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy D","family":"Allerton","sequence":"additional","affiliation":[{"name":"Vascular Metabolism Laboratory, Pennington Biomedical Research Center , Baton Rouge, LA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinheng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Biomedical Imaging Research Institute, Cedars-Sinai Medical Center , Los Angeles, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Jung R","family":"Yang","sequence":"additional","affiliation":[{"name":"Biomedical Imaging Research Institute, Cedars-Sinai Medical Center , Los Angeles, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E","family":"Bowdish","sequence":"additional","affiliation":[{"name":"Department of Cardiac Surgery, Smidt Heart Institute, Cedars-Sinai Medical Center , 127 S. San Vincente Boulevard, Los Angeles, CA 90048 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjiv J","family":"Shah","sequence":"additional","affiliation":[{"name":"Northwestern University Medicine, Feinberg School of Medicine , Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen C","family":"Woulfe","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, University of Colorado Anschutz Medical Campus , Aurora, Colorado ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy A","family":"McKinsey","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, University of Colorado Anschutz Medical Campus , Aurora, Colorado ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Yoo","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Johns Hopkins University , Baltimore, MD ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J","family":"Polhemus","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Johns Hopkins University , Baltimore, MD ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M","family":"Vondriska","sequence":"additional","affiliation":[{"name":"Departments of Anesthesiology & Perioperative Medicine, Medicine and Physiology, Molecular Biology Institute, David Geffen School of Medicine at University of California , Los Angeles, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J","family":"Lefer","sequence":"additional","affiliation":[{"name":"Department of Cardiac Surgery, Smidt Heart Institute, Cedars-Sinai Medical Center , 127 S. San Vincente Boulevard, Los Angeles, CA 90048 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Traci T","family":"Goodchild","sequence":"additional","affiliation":[{"name":"Department of Cardiac Surgery, Smidt Heart Institute, Cedars-Sinai Medical Center , 127 S. San Vincente Boulevard, Los Angeles, CA 90048 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"2026100502595935200_ehag732-B1","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.2337\/dci24-0003","article-title":"Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity","volume":"47","author":"Drucker","year":"2024","journal-title":"Diabetes Care"},{"key":"2026100502595935200_ehag732-B2","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","article-title":"Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action","volume":"20","author":"Ussher","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"2026100502595935200_ehag732-B3","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"2026100502595935200_ehag732-B4","doi-asserted-by":"publisher","first-page":"292","DOI":"10.2337\/dc24-1678","article-title":"Efficacy of GLP-1 receptor agonists on weight loss, BMI, and Waist circumference for patients with obesity or overweight: a systematic review, meta-analysis, and meta-regression of 47 randomized controlled trials","volume":"48","author":"Wong","year":"2025","journal-title":"Diabetes Care"},{"key":"2026100502595935200_ehag732-B5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0\u2005mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"key":"2026100502595935200_ehag732-B6","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/s42255-023-00812-z","article-title":"Gut hormone co-agonists for the treatment of obesity: from bench to bedside","volume":"5","author":"Nogueiras","year":"2023","journal-title":"Nat Metab"},{"key":"2026100502595935200_ehag732-B7","doi-asserted-by":"publisher","first-page":"101351","DOI":"10.1016\/j.molmet.2021.101351","article-title":"GLP-1 physiology informs the pharmacotherapy of obesity","volume":"57","author":"Drucker","year":"2022","journal-title":"Mol Metab"},{"key":"2026100502595935200_ehag732-B8","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"2026100502595935200_ehag732-B9","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"2026100502595935200_ehag732-B10","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1007\/s00125-023-05973-w","article-title":"Incretins and cardiovascular disease: to the heart of type 2 diabetes?","volume":"66","author":"Solini","year":"2023","journal-title":"Diabetologia"},{"key":"2026100502595935200_ehag732-B11","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1056\/NEJMcp2305181","article-title":"Heart failure with preserved ejection fraction","volume":"392","author":"Cannata","year":"2025","journal-title":"N Engl J Med"},{"key":"2026100502595935200_ehag732-B12","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"key":"2026100502595935200_ehag732-B13","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"2026100502595935200_ehag732-B14","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1016\/S0140-6736(24)00469-0","article-title":"Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials","volume":"403","author":"Butler","year":"2024","journal-title":"Lancet"},{"key":"2026100502595935200_ehag732-B15","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"key":"2026100502595935200_ehag732-B16","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/j.jacc.2025.03.009","article-title":"Interplay of chronic kidney disease and the effects of tirzepatide in patients with heart failure, preserved ejection fraction, and obesity: the SUMMIT trial","volume":"85","author":"Packer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026100502595935200_ehag732-B17","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.jacc.2024.11.001","article-title":"Tirzepatide REDUCES LV mass and paracardiac adipose tissue in obesity-related heart failure: SUMMIT CMR substudy","volume":"85","author":"Kramer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026100502595935200_ehag732-B18","doi-asserted-by":"publisher","first-page":"846","DOI":"10.2337\/dc25-0241","article-title":"Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of randomized trials","volume":"48","author":"Lee","year":"2025","journal-title":"Diabetes Care"},{"key":"2026100502595935200_ehag732-B19","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1210\/en.2018-00004","article-title":"GLP-1 Receptor expression within the human heart","volume":"159","author":"Baggio","year":"2018","journal-title":"Endocrinology"},{"key":"2026100502595935200_ehag732-B20","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1210\/en.2013-1934","article-title":"GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody","volume":"155","author":"Pyke","year":"2014","journal-title":"Endocrinology"},{"key":"2026100502595935200_ehag732-B21","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1161\/atv.0000615456.97862.30","article-title":"Endothelial GLP-1 (glucagon-like peptide-1) receptor mediates cardiovascular protection by liraglutide in mice with experimental arterial hypertension","volume":"40","author":"Helmstadter","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026100502595935200_ehag732-B22","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.153732","article-title":"Differential importance of endothelial and hematopoietic cell GLP-1Rs for cardiometabolic versus hepatic actions of semaglutide","volume":"6","author":"McLean","year":"2021","journal-title":"JCI Insight"},{"key":"2026100502595935200_ehag732-B23","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.201148","article-title":"Semaglutide reduces murine blood pressure through the vascular smooth muscle GLP-1 receptor","volume":"11","author":"Medak","year":"2026","journal-title":"JCI Insight"},{"key":"2026100502595935200_ehag732-B24","doi-asserted-by":"publisher","first-page":"H651","DOI":"10.1152\/ajpheart.00828.2025","article-title":"Semaglutide augments vascular proliferation and cardiac performance in a large animal model of ischemic cardiomyopathy","volume":"330","author":"Muir","year":"2026","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026100502595935200_ehag732-B25","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1093\/cvr\/cvs123","article-title":"GLP-1 and cardioprotection: from bench to bedside","volume":"94","author":"Ravassa","year":"2012","journal-title":"Cardiovasc Res"},{"key":"2026100502595935200_ehag732-B26","doi-asserted-by":"publisher","first-page":"H1159","DOI":"10.1152\/ajpheart.00574.2023","article-title":"GLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage","volume":"326","author":"Park","year":"2024","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026100502595935200_ehag732-B27","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/aps.2011.149","article-title":"Glucagon-like peptide-1 activates endothelial nitric oxide synthase in human umbilical vein endothelial cells","volume":"33","author":"Ding","year":"2012","journal-title":"Acta Pharmacol Sin"},{"key":"2026100502595935200_ehag732-B28","doi-asserted-by":"publisher","first-page":"E355","DOI":"10.1152\/ajpendo.00283.2013","article-title":"GLP-1 increases microvascular recruitment but not glucose uptake in human and rat skeletal muscle","volume":"306","author":"Sjoberg","year":"2014","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2026100502595935200_ehag732-B29","doi-asserted-by":"publisher","first-page":"E1289","DOI":"10.1152\/ajpendo.00373.2007","article-title":"Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride","volume":"293","author":"Basu","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2026100502595935200_ehag732-B30","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1016\/j.jacc.2024.08.021","article-title":"Effect of semaglutide on cardiac structure and function in patients with obesity-related heart failure","volume":"84","author":"Solomon","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026100502595935200_ehag732-B31","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/j.jacc.2024.08.028","article-title":"Inflammation in obesity-related HFpEF: the STEP-HFpEF program","volume":"84","author":"Verma","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026100502595935200_ehag732-B32","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jacc.2024.04.022","article-title":"Semaglutide and NT-proBNP in obesity-related HFpEF: insights from the STEP-HFpEF program","volume":"84","author":"Petrie","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026100502595935200_ehag732-B33","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jacbts.2020.11.012","article-title":"Novel Gottingen miniswine model of heart failure with preserved ejection fraction integrating multiple comorbidities","volume":"6","author":"Sharp","year":"2021","journal-title":"JACC Basic Transl Sci"},{"key":"2026100502595935200_ehag732-B34","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1002\/ejhf.3700","article-title":"Renal denervation improves cardiac function and exercise duration in a miniswine model of heart failure with preserved ejection fraction","volume":"27","author":"Lefer","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026100502595935200_ehag732-B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2025.04.011","article-title":"Hydrogen sulfide deficiency and therapeutic targeting in cardiometabolic HFpEF: evidence for synergistic benefit with GLP-1\/glucagon agonism","volume":"10","author":"Doiron","year":"2025","journal-title":"JACC Basic Transl Sci"},{"key":"2026100502595935200_ehag732-B36","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.15420\/cfr.2022.12","article-title":"Microvascular dysfunction in heart failure with preserved ejection fraction: pathophysiology, assessment, prevalence and prognosis","volume":"8","author":"Bilak","year":"2022","journal-title":"Card Fail Rev"},{"key":"2026100502595935200_ehag732-B37","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/s44161-024-00516-x","article-title":"Myocardial ultrastructure of human heart failure with preserved ejection fraction","volume":"3","author":"Meddeb","year":"2024","journal-title":"Nat Cardiovasc Res"},{"key":"2026100502595935200_ehag732-B38","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.2147\/JIR.S459989","article-title":"Prognostic value of inflammatory cytokines in predicting hospital readmissions in heart failure with preserved ejection fraction","volume":"17","author":"Zhao","year":"2024","journal-title":"J Inflamm Res"},{"key":"2026100502595935200_ehag732-B39","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1093\/cvr\/cvad093","article-title":"Immune profiling of murine cardiac leukocytes identifies triggering receptor expressed on myeloid cells 2 as a novel mediator of hypertensive heart failure","volume":"119","author":"Smart","year":"2023","journal-title":"Cardiovasc Res"},{"key":"2026100502595935200_ehag732-B40","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.119.006414","article-title":"Obese-inflammatory phenotypes in heart failure with preserved ejection fraction","volume":"13","author":"Sabbah","year":"2020","journal-title":"Circ Heart Fail"},{"key":"2026100502595935200_ehag732-B41","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.cardfail.2015.07.012","article-title":"Increased Serum levels of the notch ligand DLL1 are associated with diastolic dysfunction, reduced exercise capacity, and adverse outcome in chronic heart failure","volume":"22","author":"Norum","year":"2016","journal-title":"J Card Fail"},{"key":"2026100502595935200_ehag732-B42","doi-asserted-by":"publisher","first-page":"954","DOI":"10.2459\/JCM.0000000000000549","article-title":"Elevated serum osteoprotegerin is associated with increased left ventricular mass index and myocardial stiffness","volume":"18","author":"Kamimura","year":"2017","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"2026100502595935200_ehag732-B43","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nature24676","article-title":"IL-11 is a crucial determinant of cardiovascular fibrosis","volume":"552","author":"Schafer","year":"2017","journal-title":"Nature"},{"key":"2026100502595935200_ehag732-B44","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1007\/s10620-013-2669-y","article-title":"Disrupted circadian rhythmicity of the intestinal glucose transporter SGLT1 in zucker diabetic fatty rats","volume":"58","author":"Bhutta","year":"2013","journal-title":"Dig Dis Sci"},{"key":"2026100502595935200_ehag732-B45","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.cmet.2018.04.015","article-title":"The BCKDH kinase and phosphatase integrate BCAA and lipid metabolism via regulation of ATP-citrate lyase","volume":"27","author":"White","year":"2018","journal-title":"Cell Metab"},{"key":"2026100502595935200_ehag732-B46","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.phrs.2017.12.018","article-title":"Kruppel-like factor 15: regulator of BCAA metabolism and circadian protein rhythmicity","volume":"130","author":"Fan","year":"2018","journal-title":"Pharmacol Res"},{"key":"2026100502595935200_ehag732-B47","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1161\/CIRCRESAHA.124.324829","article-title":"Systems biology approach uncovers candidates for liver-heart interorgan crosstalk in HFpEF","volume":"135","author":"Strocchi","year":"2024","journal-title":"Circ Res"},{"key":"2026100502595935200_ehag732-B48","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1161\/CIRCULATIONAHA.122.062874","article-title":"Cardiometabolic HFpEF: NASH of the heart","volume":"147","author":"Capone","year":"2023","journal-title":"Circulation"},{"key":"2026100502595935200_ehag732-B49","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/dom.15728","article-title":"Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies","volume":"26 Suppl 4","author":"Neeland","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"2026100502595935200_ehag732-B50","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1080\/14656566.2024.2343092","article-title":"A systematic review of the effect of semaglutide on lean mass: insights from clinical trials","volume":"25","author":"Bikou","year":"2024","journal-title":"Expert Opin Pharmacother"},{"key":"2026100502595935200_ehag732-B51","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1001\/jamacardio.2023.0957","article-title":"Skeletal muscle mitochondrial respiration and exercise intolerance in patients with heart failure with preserved ejection fraction","volume":"8","author":"Scandalis","year":"2023","journal-title":"JAMA Cardiol"},{"key":"2026100502595935200_ehag732-B52","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (harmony outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"2026100502595935200_ehag732-B53","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"for the SELECT Trial Investigators. Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2026100502595935200_ehag732-B54","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1093\/cvr\/cvaf102","article-title":"Premature cell senescence promotes vascular smooth muscle cell phenotypic modulation and resistance to re-differentiation","volume":"121","author":"Kaistha","year":"2025","journal-title":"Cardiovasc Res"},{"key":"2026100502595935200_ehag732-B55","doi-asserted-by":"publisher","first-page":"18946","DOI":"10.1038\/s41598-021-98177-4","article-title":"High levels of osteoprotegerin are associated with coronary artery calcification in patients suspected of a chronic coronary syndrome","volume":"11","author":"Dekker","year":"2021","journal-title":"Sci Rep"},{"key":"2026100502595935200_ehag732-B56","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1042\/CS20210643","article-title":"Osteoprotegerin regulates vascular function through syndecan-1 and NADPH oxidase-derived reactive oxygen species","volume":"135","author":"Alves-Lopes","year":"2021","journal-title":"Clin Sci (Lond)"},{"key":"2026100502595935200_ehag732-B57","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s12265-017-9748-y","article-title":"The notch ligands DLL1 and periostin are associated with symptom severity and diastolic function in dilated cardiomyopathy","volume":"10","author":"Norum","year":"2017","journal-title":"J Cardiovasc Transl Res"},{"key":"2026100502595935200_ehag732-B58","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12597","article-title":"Regulation of monocyte cell fate by blood vessels mediated by notch signalling","volume":"7","author":"Gamrekelashvili","year":"2016","journal-title":"Nat Commun"},{"key":"2026100502595935200_ehag732-B59","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1038\/s42003-025-08387-z","article-title":"Identification of conserved and tissue-restricted transcriptional profiles for lipid associated macrophages","volume":"8","author":"Xu","year":"2025","journal-title":"Commun Biol"},{"key":"2026100502595935200_ehag732-B60","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1161\/CIRCRESAHA.123.323184","article-title":"Single-cell gene-regulatory networks of advanced symptomatic atherosclerosis","volume":"134","author":"Mocci","year":"2024","journal-title":"Circ Res"},{"key":"2026100502595935200_ehag732-B61","doi-asserted-by":"publisher","first-page":"H1073","DOI":"10.1152\/ajpheart.00075.2025","article-title":"TREM2 as a regulator of obesity-induced cardiac remodeling: mechanisms and therapeutic insights","volume":"328","author":"Chung","year":"2025","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026100502595935200_ehag732-B62","doi-asserted-by":"publisher","first-page":"3296","DOI":"10.1002\/ehf2.15342","article-title":"Proteins associated with rehospitalization, mortality and diuretic resistance in acutely decompensated heart failure","volume":"12","author":"Hubbell","year":"2025","journal-title":"ESC Heart Fail"},{"key":"2026100502595935200_ehag732-B63","doi-asserted-by":"publisher","DOI":"10.3389\/ebm.2024.10121","article-title":"Legumain in cardiovascular diseases","volume":"249","author":"Zhou","year":"2024","journal-title":"Exp Biol Med (Maywood)"},{"key":"2026100502595935200_ehag732-B64","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/s41419-020-03211-4","article-title":"Legumain is a predictor of all-cause mortality and potential therapeutic target in acute myocardial infarction","volume":"11","author":"Yang","year":"2020","journal-title":"Cell Death Dis"},{"key":"2026100502595935200_ehag732-B65","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1161\/CIRCULATIONAHA.115.020226","article-title":"Catabolic defect of branched-chain amino acids promotes heart failure","volume":"133","author":"Sun","year":"2016","journal-title":"Circulation"},{"key":"2026100502595935200_ehag732-B66","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1161\/CIRCRESAHA.121.319817","article-title":"Mitochondrial H(2)S regulates BCAA catabolism in heart failure","volume":"131","author":"Li","year":"2022","journal-title":"Circ Res"},{"key":"2026100502595935200_ehag732-B67","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.cmet.2016.11.005","article-title":"Defective branched-chain amino acid catabolism disrupts glucose metabolism and sensitizes the heart to ischemia-reperfusion injury","volume":"25","author":"Li","year":"2017","journal-title":"Cell Metab"},{"key":"2026100502595935200_ehag732-B68","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1161\/CIRCULATIONAHA.122.061846","article-title":"Myocardial metabolomics of human heart failure with preserved ejection fraction","volume":"147","author":"Hahn","year":"2023","journal-title":"Circulation"},{"key":"2026100502595935200_ehag732-B69","doi-asserted-by":"publisher","first-page":"6257","DOI":"10.7150\/thno.105894","article-title":"BCAA catabolism targeted therapy for heart failure with preserved ejection fraction","volume":"15","author":"Wang","year":"2025","journal-title":"Theranostics"},{"key":"2026100502595935200_ehag732-B70","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.jacbts.2021.07.004","article-title":"Molecular signature of HFpEF: systems biology in a cardiac-centric large animal model","volume":"6","author":"Gibb","year":"2021","journal-title":"JACC Basic Transl Sci"},{"key":"2026100502595935200_ehag732-B71","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1161\/CIRCULATIONAHA.124.071741","article-title":"Lymphatic endothelial branched-chain amino acid catabolic defects undermine cardiac lymphatic integrity and drive HFpEF","volume":"151","author":"Guo","year":"2025","journal-title":"Circulation"},{"key":"2026100502595935200_ehag732-B72","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1093\/eurheartj\/ehaf524","article-title":"Left ventricular hypertrophy and myocardial fibrosis in heart failure with preserved ejection fraction: mechanisms and treatment","volume":"47","author":"Peikert","year":"2026","journal-title":"Eur Heart J"},{"key":"2026100502595935200_ehag732-B73","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1161\/CIRCRESAHA.121.318159","article-title":"From systemic inflammation to myocardial fibrosis: the heart failure with preserved ejection fraction paradigm revisited","volume":"128","author":"Paulus","year":"2021","journal-title":"Circ Res"},{"key":"2026100502595935200_ehag732-B74","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aay7205","article-title":"HDAC inhibition improves cardiopulmonary function in a feline model of diastolic dysfunction","volume":"12","author":"Wallner","year":"2020","journal-title":"Sci Transl Med"},{"key":"2026100502595935200_ehag732-B75","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aao0144","article-title":"Histone deacetylase activity governs diastolic dysfunction through a nongenomic mechanism","volume":"10","author":"Jeong","year":"2018","journal-title":"Sci Transl Med"},{"key":"2026100502595935200_ehag732-B76","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"2026100502595935200_ehag732-B77","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1038\/s41591-025-03799-0","article-title":"Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"31","author":"Jara","year":"2025","journal-title":"Nat Med"},{"key":"2026100502595935200_ehag732-B78","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1016\/j.numecd.2022.03.003","article-title":"Lipids and diastolic dysfunction: recent evidence and findings","volume":"32","author":"Daneii","year":"2022","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2026100502595935200_ehag732-B79","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1161\/CIRCRESAHA.116.306842","article-title":"Lipid use and misuse by the heart","volume":"118","author":"Schulze","year":"2016","journal-title":"Circ Res"},{"key":"2026100502595935200_ehag732-B80","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.cmet.2020.05.001","article-title":"GLP-1 Receptor signaling in astrocytes regulates fatty acid oxidation, mitochondrial integrity, and function","volume":"31","author":"Timper","year":"2020","journal-title":"Cell Metab"},{"key":"2026100502595935200_ehag732-B81","doi-asserted-by":"publisher","first-page":"354","DOI":"10.4093\/dmj.2023.0277","article-title":"Glucagon-like peptide-1: new regulator in lipid metabolism","volume":"48","author":"Bu","year":"2024","journal-title":"Diabetes Metab J"},{"key":"2026100502595935200_ehag732-B82","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/dom.14580","article-title":"Cardiovascular risk profiles: a cross-sectional study evaluating the generalizability of the glucagon-like peptide-1 receptor agonist cardiovascular outcome trials REWIND, LEADER and SUSTAIN-6 to the real-world type 2 diabetes population in the United Kingdom","volume":"24","author":"Webb","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"2026100502595935200_ehag732-B83","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.1007\/s12325-022-02196-0","article-title":"A retrospective observational study examining the generalizability of glucagon-like peptide 1 receptor agonist cardiovascular outcome trials to the real-world population with type 2 diabetes in Spain: the REPRESENT study","volume":"39","author":"Romera","year":"2022","journal-title":"Adv Ther"},{"key":"2026100502595935200_ehag732-B84","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"2026100502595935200_ehag732-B85","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2026100502595935200_ehag732-B86","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2026100502595935200_ehag732-B87","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"key":"2026100502595935200_ehag732-B88","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N Engl J Med"},{"key":"2026100502595935200_ehag732-B89","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1111\/dom.13649","article-title":"Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States","volume":"21","author":"Boye","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"2026100502595935200_ehag732-B90","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jdiacomp.2014.01.009","article-title":"Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials","volume":"28","author":"Fonseca","year":"2014","journal-title":"J Diabetes Complications"},{"key":"2026100502595935200_ehag732-B91","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.2337\/dc09-1914","article-title":"DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks","volume":"33","author":"Buse","year":"2010","journal-title":"Diabetes Care"},{"key":"2026100502595935200_ehag732-B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2022.108390","article-title":"Impact of Glucagon-like peptide 1 receptor agonists on peripheral arterial disease in people with diabetes mellitus: a narrative review","volume":"37","author":"Liarakos","year":"2023","journal-title":"J Diabetes Complications"},{"key":"2026100502595935200_ehag732-B93","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.1545","article-title":"Liraglutide for lower limb perfusion in people with type 2 diabetes and peripheral artery disease: the STARDUST randomized clinical trial","volume":"7","author":"Caruso","year":"2024","journal-title":"JAMA Netw Open"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehag732\/71589200\/ehag732.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehag732\/71589200\/ehag732.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T07:00:09Z","timestamp":1791183609000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article\/doi\/10.1093\/eurheartj\/ehag732\/8862375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":93,"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehag732","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]},"article-number":"ehag732"}}